Immunotherapy plus chemotherapy as first-line treatment choice for advanced disease without oncogene mutations, irrespective of ethnicity and PD-L1 status 

The ESMO Award for Immuno-Oncology 2021 is given to Prof. Wolf H. Fridman, whose research has made significant contributions to unveiling the prognostic and predictive role of the tumour microenvironment 

For the recipient of the ESMO Award for Immuno-Oncology 2020, Dr Jedd Wolchok, one of the biggest challenges in the field is knowing how and when to de-escalate immunotherapy 

The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration 

In the first interim analysis of the ORIENT-31 trial, progression-free survival was slightly improved in patients who progressed after EGFR TKI, but mature results are needed to confirm whether combination therapy represents a new therapeutic option in this setting

However, regulatory and financial issues will shape when and where this happens  

Knock-on effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines  

The Pan-Asian adaptation of the ESMO guidelines introduces some changes to the standard of care in Europe, including diagnostic tests and the use of cytoreductive nephrectomy 

The Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines is presented at the ESMO Asia Virtual Oncology Week 2021 

Risk assessment and alternative fluoropyrimidine regimens are the main changes in the Pan-Asian adapted ESMO Clinical Practice Guidelines, reinforcing ESMO’s commitment in the region